Dergiler / Göztepe Tıp Dergisi / 2007 / Cilt: 22 - Sayı: 3

Kronik hepatit B’de konvansiyonel interferon tedavisi

HBsAg seroconversion with convensional interferon treatment for chronic hepatit B

Sayfa
107–108
Yayın Tarihi
2022-10-17
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

We present a case who cleared HBsAg and achieved anti HBs positivity after treatment with convensional interferon.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Each year HBsAg clearance appears spontenously between the range of 1-2 percent of hepatit B and, also antiHBs appears in 1/3 rate of these cases.
📊
Temel Bulgular & Veri:HBsAg serokonversion is seen in 4 percent of patients treated with convensional interferon and this rate is also similar for the treatment with peginterferon.
💡
Sonuç & Katkı:We present a case who cleared HBsAg and achieved anti HBs positivity after treatment with convensional interferon.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Each year HBsAg clearance appears spontenously between the range of 1-2 percent of hepatit B and, also antiHBs appears in 1/3 rate of these cases. HBsAg serokonversion is seen in 4 percent of patients treated with convensional interferon and this rate is also similar for the treatment with peginterferon. We present a case who cleared HBsAg and achieved anti HBs positivity after treatment with convensional interferon.

🔖

Bu Makaleye Atıf Yap

ENÇ, F. Y., YEŞİLOĞLU, C. (2022). Kronik hepatit B’de konvansiyonel interferon tedavisi. Göztepe Tıp Dergisi, Cilt: 22 - Sayı: 3, 107–108. https://ajindex.com/articles/526285

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (4)

  1. Eddleston ALWF and Dixon B: Interferons in the treatment of chronic viral infection of liver, 1. edit, UK, pennine pres 1990
  2. Dianzani F Antonelli G, Capobianchi MR: The biological basis fort he clinical use of interferon. J Hepatol (suppl 1):5-10, 1990
  3. Rogers et al: Hepatitis B virüs: Clinical disease. Richard AW (ed). Viral Hepatitis,1. edit, NewYork, Marcel Dekker 1997: 134-46
  4. İkeda K, Saitoh S, Suzuki Y, et al: Interferon decreases hepatocelüler carcinogenesis in patients with cirrhosis caused by the hepatitis B virüs: a pilot study. Cancer 82:887-35, 1998.